Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Reexamination Certificate
2002-03-19
2003-03-18
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
C424S451000, C424S464000, C424S488000, C514S175000, C514S951000
Reexamination Certificate
active
06534093
ABSTRACT:
DESCRIPTION
Technical Field
The present invention relates to pharmaceutical compositions comprising the compound eplerenone as an active ingredient, and more particularly to pharmaceutical compositions containing micronized eplerenone, methods of treatment comprising administering such pharmaceutical compositions to a subject in need thereof, and the use of such compositions in the manufacture of medicaments.
BACKGROUND OF THE INVENTION
The compound methyl hydrogen 9,11&agr;-epoxy-17&agr;-hydroxy-3-oxopregn-4-ene-7&agr;,21-dicarboxylate, &ggr;-lactone (also referred to herein as eplerenone) was first reported in Grob et al., U.S. Pat. No. 4,559,332 that describes and claims a class of 9,11-epoxy steroid compounds and their salts together with processes for the preparation of such compounds. These 9,11-epoxy steroid compounds are described as aldosterone antagonists that can be administered in a therapeutically effective amount to treat pathological conditions associated with hyperaldosteronism such as hypertension, cardiac insufficiency and cirrhosis of the liver. U.S. Pat. No. 4,559,332 contains general references to formulations for the administration of these 9,11-epoxy steroid compounds such as tablets and capsules.
Eplerenone corresponds in structure to Formula I, below:
Spironolactone, another 20-spiroxane-steroid having activity as an aldosterone antagonist, is commercially available for the treatment of hypertension. Spironolactone corresponds in structure to Formula II, below:
Spironolactone, however, exhibits antiandrogenic activity that can result in gynecomastia and impotence in men, and weak progestational activity that produces menstrual irregularities in women. Commercial formulations of spironolactone (sold under the name Aldactone™) contain 25, 50 or 100 mg doses of spironolactone in a matrix comprising, among other carrier materials, calcium sulfate dihydrate as a diluent, maize starch as a disintegrant, povidone K-30 as a binding agent, magnesium stearate as a lubricant, and flavor, colorant, and coating ingredients that include hydroxypropylmethylcellulose and polyethylene glycol 400.
de Gasparo et al., in Journal of Steroid Biochemistry 32 (1B), 223-227 (1989) report the use of spironolactone and epoxymexrenone in receptor binding studies. Those materials, with spironolactone in a commercial formulation with a particle size of 5 microns and the epoxymexrenone at a particle size of 20 microns in a non-formulated composition, were also used in vivo to study excretion of sodium in urine.
BRIEF SUMMARY OF THE INVENTION
The effective administration of eplerenone to a subject has been complicated by the compound's low solubility and low compressibility as well as by its other physical and chemical properties. Pharmaceutical compositions comprising micronized eplerenone and a pharmaceutically acceptable carrier material, however, have been discovered that can effectively deliver a therapeutically preferred amount of the compound to the subject. In addition, unique combinations of carrier material with the micronized eplerenone have been found that provide still better solubilization characteristics. These combinations of active compound and carrier material have been found to possess improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, safety, as well as other improved pharmacokinetic, chemical and/or physical properties. The present invention comprises these pharmaceutical compositions, unit dosage forms based thereon, and methods for the preparation and use of both.
REFERENCES:
patent: 4559332 (1985-12-01), Grob et al.
patent: 4753802 (1988-06-01), Stephans et al.
patent: 4828836 (1989-05-01), Elger et al.
patent: 4847093 (1989-07-01), Ayer et al.
patent: 4975284 (1990-12-01), Stead et al.
patent: 5057317 (1991-10-01), Iida
patent: 5082668 (1992-01-01), Wong et al.
patent: 5160744 (1992-11-01), Jao et al.
patent: 5190765 (1993-03-01), Jao et al.
patent: 5324718 (1994-06-01), Loftsson
patent: 5354556 (1994-10-01), Sparks et al.
patent: 6410054 (2002-06-01), Thosar et al.
patent: 0 572 942 (1993-12-01), None
patent: WO 92/00729 (1992-01-01), None
patent: WO 92/13547 (1992-08-01), None
patent: WO 94/27582 (1994-12-01), None
patent: WO 95/15166 (1995-06-01), None
patent: WO 98/25948 (1998-06-01), None
de Gasparo et al. (1987). Three new epoxy-spironolactone derivatives: characterization in vivo and in vitro. Journal of Pharmachology and Experimental Therapeutics 240, 650-656.
de Gasparo et al. (1989). Antialdosterones: incidence and prevention of sexual side effects. Journal of Steroid Bichemistry 32 (1B), 223-227.
Delyani, John A. (1998) Anti-aldosterone therapy in the treatment of heart failure: new thoughts on an old hormone. In Expert Opin. Invest. Drugs. 7(5), pp. 753-759.
Gokhale Rajeev D.
Thosar Shilpa S.
Tolbert Dwain S.
Channavajjala Lakshmi
Forbes James C.
G.D. Searle & Co.
Page Thurman K.
LandOfFree
Immediate release eplerenone compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immediate release eplerenone compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immediate release eplerenone compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3007939